T-cell checkpoint inhibitors in metastatic renal cell carcinoma

Current Opinion in Urology

Volumn 25, Issue 5, 2015, Pages 411-415

  Grünwald, Viktor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Checkpoint inhibitors; Cytotoxic T lymphocyte associated protein 4; Programmed death ligand 1; Programmed death 1

Indexed keywords

BIOLOGICAL MARKER; BMS 936559; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; HUMAN; KIDNEY METASTASIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; ADVERSE EFFECTS; CARCINOMA, RENAL CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROCEDURES; SECONDARY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84942594749     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000199     Document Type: Review

References (21)

1. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722-731.
2. Eichelberg C, Vervenne WL, De Santis M, et al. SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in the treatment of metastatic RCC. Eur Urol 2015. [Epub ahead of print]. doi: 10.1016/j.eururo .2015.04.017. 3.
3. Grünwald V, McKay RR, Krajewski KM, et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 2015; 67:952-958. This stud y defines the prognostic role of deep tumour repsonse in mRCC.
4. Grünwald V, Merseburger AS. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors: is there more to come Eur J Cancer 2013; 49:2504-2511.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.
6. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101:17174-1 7179. A pivotal finding of the study is the unfavourable prognosis of PD-L1 positive mRCC.
7. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumorinfiltrating immune cells and is associated with poor outc ome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13:1757-1761.
8. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-5074. This is among the first articles exploring the relationship of PD-L1 topography in different tumour types. It provides relevant insights on how to define PD-L1 positivity and its colocalization to immune cells. It is a current milestone for al l who are dealing with the issue of biomarker development of PD-L1.
9. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33:1430-1437. It is a key for PD-1 inhibition in mRCC. It provides insights into the role of dose and tumour response to nivolumab in mRCC, while maintaining tolerability.
10. Topalian SL, Sznol M, Brah mer JR, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial. J Clin Oncol 2013; 31: (suppl; abstr 3002).
11. Brahmer JR , Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
12. Cho DC, Sosman JA, Sznol M, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31: (suppl; abstr 4505).
13. Topalian SL, Hodi F S, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
14. Yang JC, Hughes M, Kammula U, et al. Ipilimumab ( anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825-830. This is the reference trial for single-Agent ipilimumab activity in mRCC.
15. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133. This is the proof of concept for dual checkpoint inhibition and provides first clinical evidence for this approach.
16. Hammers H, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 32: 2014; 5s: (suppl; abstr 4504).
17. Motzer RJ, Escudier BJ, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2 008; 372:449-456.
18. Motzer RJ, Escudier B, Tomszak P, et al. Axitinib versus sorafenib as secondline treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a ran domised phase 3 trial. Lancet Oncol 2013; 14:552-562.
19. Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 32: 2014; 5s: (suppl; abstr 5010).
20. Lieu C,Bendell JC,Powderly JD,et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab and/or chemotherapy in patients with locally advanced or met astatic solid tumors Ann Oncol 2014 25: (suppl-4): iv361-iv372. 10.1093/annonc/mdu342.
21. McDermott DF, Sznol M, Sosman JA, et al. Immune correlates and long term follow up of a phase Ia study of mpdl3280a, an engineered pd-l1 antibody, in patients with metastatic renal cell carcinoma (MRCC). Ann Oncol 2014; 25: (suppl-4): iv280-iv304. 10.1093/annonc/mdu337.